Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 Next >
Alvotech Announces Changes to the Leadership Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $100 Million Convertible Bond Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Tickers ALVO JNJ TEVA
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
Tickers ALVO
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
Tickers ALVO
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.